Log In
BCIQ
Print this Print this
 

milatuzumab-SN-38

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionA milatuzumab conjugate of SN-38, a topo I inhibitor, with a pH-sensitive linker
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today